The ITER neutral beam (NB) injectors are the first injectors that will have to operate in a hostile radiation environment and they will become highly radioactive due to the neutron flux from ITER. The injectors will use a single large ion source and accelerator that will produce 40 A 1 MeV Dbeams for pulse lengths of up to 3600 s. Significant changes have been made to the ITER heating NB injector (HNB) over the past 4 years. The main changes are: o Modifications to allow installation and maintenance of the beamline components with an overhead crane. o The RF driven negative ion source developed by IPP Garching has replaced the filamented ion source from JAEA, Naka as the reference design. o The ion source and extractor power supplies will be located in an air insulated high voltage (-1 MV) deck located outside the tokamak building instead of inside an SF 6 insulated HV deck located above the injector. The development of the ITER accelerators and ion sources has been carried out on relatively low powered test stands, making impossible the full demonstration of the ITER requirements. Padua Research on Injectors with Megavolt Acceleration (PRIMA, ex-NBTF) will be built to allow the R&D necessary to finalise the development of the full power system
The ITER Neutral Beam Test Facility (NBTF), called PRIMA (Padova Research on ITER Megavolt Accelerator), is hosted in Padova, Italy and includes two experiments: MITICA, the full-scale prototype of the ITER heating neutral beam injector, and SPIDER, the full-size radio frequency negative-ions source. The NBTF realization and the exploitation of SPIDER and MITICA have been recognized as necessary to make the future operation of the ITER heating neutral beam injectors efficient and reliable, fundamental to the achievement of thermonuclear-relevant plasma parameters in ITER. This paper reports on design and R&D carried out to construct PRIMA, SPIDER and MITICA, and highlights the huge progress made in just a few years, from the signature of the agreement for the NBTF realization in 2011, up to now-when the buildings and relevant infrastructures have been completed, SPIDER is entering the integrated commissioning phase and the procurements of several MITICA components are at a well advanced stage.
The ITER project requires additional heating by two neutral beam injectors, each accelerating to 1 MV a 40 A beam of negative deuterium ions, to deliver to the plasma a power of about 17 MW for one hour. As these requirements have never been experimentally met, it was Nuclear Fusion Progress in the realization of the PRIMA neutral beam test facility
The requirements of ITER neutral beam injectors (1 MeV, 40 A negative deuterium ion current for 1 h) have never been simultaneously attained; therefore, a dedicated Neutral Beam Test Facility (NBTF) was set up at Consorzio RFX (Padova, Italy). The NBTF includes two experiments: SPIDER (Source for the Production of Ions of Deuterium Extracted from Rf plasma), the full-scale prototype of the source of ITER injectors, with a 100 keV accelerator, to investigate and optimize the properties of the ion source; and MITICA, the full-scale prototype of the entire injector, devoted to the issues related to the accelerator, including voltage holding at low gas pressure. The present paper gives an account of the status of the procurements, of the timeline, and of the voltage holding tests and experiments for MITICA. As for SPIDER, the first year of operation is described, regarding the solution of some issues connected with the radiofrequency power, the source operation, and the characterization of the first negative ion beam.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations鈥揷itations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.